European MS Platform

📍 RiMS 2026 | 11–13 June | Prague The leading European gathering on MS rehabilitation — from neuroplasticity to real-world outcomes that matter most for people with MS. Highlight: "Coping with MS" panel, chaired by EMSP CEO @Lili_Bxl . 🔗 rehabinms.org/meetings-detai… #RiMS2026

516 patients per nurse. That's the average caseload uncovered by our survey of 108 MS nurses across 15 countries. Clinical trials, psychological support and benefits advice routinely left undone Systemic change is overdue #InternationalNursesDay Learm more bit.ly/4fghEwG

1.2M people live with MS in Europe and access to treatment still depends on where you live. This May, our members @DMSG_BV 🇩🇪 & @MSIRELAND 🇮🇪 are taking on #TheMay50K, led by @MSIntFederation Every kilometre moves research and equity forward. Register- bit.ly/4tYB8ul

@EUBrainFdn @EU_Commission @EUPHActs @Lili_Bxl Survey findings and reccomendations-bit.ly/4tXx4KG

5/ Investing in MS nurses = investing in the lives of people with MS. 📄 Full survey & recommendations: #EUPHW #HealthcareWorkforce @EUBrainFdn @EU_Commission @EUPHActs @Lili_Bxl

1/ Final day of European Public Health Week 🇪🇺 — today's theme: the healthcare workforce. Specialised MS nurses are the backbone of modern MS care. Without them, no therapy reaches its full potential. 🧵

@annarevillab @eumsyouth Survey findings and reccomendations- bit.ly/4tXx4KG

4/ 👉 Explore the Learning Corner: emsp.org/learning-corne…

3/ Curated by EMSP and our partners. Evidence-based. Updated regularly as our projects progress.

1/ It's European Public Health Week 🇪🇺 — today's theme: disinformation. For people living with MS, NMOSD, and MOGAD, sorting fact from fiction online is a daily challenge. Misinformation isn't just confusing — it can be harmful. 🧵 #EUPHW

🔍 𝐖𝐡𝐚𝐭 𝐜𝐡𝐚𝐥𝐥𝐞𝐧𝐠𝐞𝐬 𝐫𝐞𝐦𝐚𝐢𝐧 𝐢𝐧 𝐝𝐢𝐚𝐠𝐧𝐨𝐬𝐢𝐧𝐠 𝐌𝐎𝐆𝐀𝐃? Our latest Spotlight, 𝘔𝘖𝘎𝘈𝘋: 𝘌𝘮𝘦𝘳𝘨𝘪𝘯𝘨 𝘐𝘯𝘴𝘪𝘨𝘩𝘵𝘴 𝘢𝘯𝘥 𝘌𝘷𝘰𝘭𝘷𝘪𝘯𝘨 𝘊𝘩𝘢𝘭𝘭𝘦𝘯𝘨𝘦𝘴, explores the latest developments in MOGAD diagnosis, biomarkers, and therapeutic approaches. Read the Spotlight here: ectrims.eu/mogad-emerging… "While the criteria are a big step forward, obstacles remain in differentiating MOGAD from MS, which is crucial given the differences in treatment," says Professor Anne-Katrin Pröbstel of Universitätsklinikum Bonn and Universitätsspital Basel (USB). "A key unresolved question in MOGAD management is: how long do we treat people for, both after an initial attack and in those who experience relapses?" adds Dr. Wei Yeh of Monash University in Melbourne. The ECTRIMS Spotlight Series is curated and authored by our Scientific Content Writer, Stefania de Vito. #MultipleSclerosis #MOGAD #MSResearch #Neurology #MSSpotlight #Neuroimmunology #ECTRIMS

4/ 🎧 Listen to our Let's Talk MS episode on managing mental health with MS: bit.ly/4uyQwNU 🤝 Young & living with MS? Join our YPN for peer support and connection: emsp.org/projects/ypn/ @EUPHActs

3/ This is especially urgent for young people. Our IMSS findings show younger people with MS face higher rates of depression, isolation, and anxiety.

It's European Public Health Week 🇪🇺 and we're starting with mental health. A new study from EMSP's Partner Project, WISDOM reveals something powerful: depression and anxiety often appear before an MS diagnosis — part of MS's earliest trajectory, not just a consequence. 🧵